Valuation: Healius Limited

Market Cap 276M 193M 168M 157M 144M 271M 18.41B 1.85B 724M 9.18B 725M 709M 30.27B P/E 2026 *
-10x
P/E 2027 * -106x
Enterprise Value 1.18B 828M 720M 672M 617M 1.16B 78.95B 7.92B 3.1B 39.37B 3.11B 3.04B 130B EV / Sales 2026 *
0.86x
EV / Sales 2027 * 0.85x
Free-Float
77.51%
Yield 2026 *
-
Yield 2027 * 0.35%
3 years 0.84
Extreme 0.84
0.97
5 years 0.84
Extreme 0.84
0.97
10 years 0.84
Extreme 0.84
2.95
Manager TitleAgeSince
Chief Executive Officer - 05/03/2024
Director of Finance/CFO - 13/10/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 21/08/2018
Chairman 65 28/11/2023
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-13.40%-.--% - - 193M
+0.97%+4.78%+100.89%+522.95% 38.72B
-0.58%+2.08%+17.56%+42.81% 24.87B
+1.14%+0.36%-19.20%-35.22% 7.55B
+4.74%+8.60%+22.14%+106.11% 5.25B
-0.35%+4.97%+22.26%+61.28% 3.33B
+3.60%+20.55%+206.98%-0.56% 2.04B
+4.22%+12.09%-33.21%+832.14% 2.01B
-0.90%+4.05%-12.50%-60.91% 1.89B
+0.76%+4.48%+21.28%+7.94% 1.85B
Average +0.03%+6.36%+36.24%+164.06% 9.72B
Weighted average by Cap. +0.78%+4.18%+54.38%+267.22%

Financials

2026 *2027 *
Net sales 1.38B 965M 838M 783M 718M 1.35B 91.94B 9.23B 3.61B 45.85B 3.62B 3.54B 151B 1.42B 994M 864M 806M 740M 1.4B 94.72B 9.51B 3.72B 47.24B 3.73B 3.65B 156B
Net income -27.45M -19.21M -16.69M -15.58M -14.31M -26.98M -1.83B -184M -71.97M -913M -72.15M -70.55M -3.01B -447K -313K -272K -254K -233K -440K -29.84M -3M -1.17M -14.88M -1.18M -1.15M -49.09M
Net Debt 908M 635M 552M 515M 473M 892M 60.55B 6.08B 2.38B 30.19B 2.39B 2.33B 99.59B 930M 651M 565M 528M 485M 914M 62.01B 6.22B 2.44B 30.93B 2.44B 2.39B 102B
Logo Healius Limited
Healius Limited is a healthcare company. The Company's specialized pathology businesses deliver healthcare services across Australia. It provides pathology services, including specialty pathology and clinical trials. It offers medical laboratory and pathology services through a variety of specialty brands. It provides medical laboratory and pathology services across key diagnostic activities. These include anatomical pathology (histopathology and cytology), clinical pathology (biochemistry, hematology, immunology and microbiology), genomic diagnostics and veterinary pathology. Its brands include Abbot, Agilex Biolabs, Dorevitch, Gastrolab, Genomic Diagnostics, IQ Pathology, Kossard Dermatopathology, Laverty Pathology, QML Pathology, TML Pathology, Vetnostics Pathology and Western Diagnostic Pathology (WDP). These brands operate in Queensland, New South Wales (including the Australian Capital Territory), Victoria, Western Australia and Northern Territory, Tasmania, and South Australia.
Employees
5,962
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
10
Last Close Price
0.3800AUD
Average target price
0.4962AUD
Spread / Average Target
+30.57%

Quarterly revenue - Rate of surprise